

Updates and Evolving Care Considerations in the Mitigation of Hyperkalemia in Patients with End-Stage Renal Disease (ESRD) on Dialysis - Case Review #2

References

Post 6

Clase CM, Carrero J-J, Ellison DH. Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference. *Kidney Int.* 2020;97:42-61. doi:10.1016/j.kint.2019.09.018

Post 7

Gaudreault-Tremblay MM, Foster BJ. Benefits of continuing RAAS inhibitors in advanced CKD. *Clin J Amer Soc Nephrol.* 2020;15(5):592-593; doi:10.2215/CJN.02920320

Epstein M, Reaven NL, Funk SE, McGaughey KJ, Oestreicher N, Knispel J. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. *Am J Manag Care.* 2015;21(11 Suppl):S212-S220.

Post 9

Epstein M, Reaven NL, Funk SE, McGaughey KJ, Oestreicher N, Knispel J. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. *Am J Manag Care.* 2015;21(11 Suppl):S212-S220.

Post 12

Pitt B, Bakris GL. New potassium binders for the treatment of hyperkalemia: current data and opportunities for the future. *Hypertension.* 2015;66(4):731-738. doi:10.1161/HYPERTENSIONAHA.115.04889

Post 14

Pitt B, Bakris GL. New potassium binders for the treatment of hyperkalemia: current data and opportunities for the future. *Hypertension.* 2015;66(4):731-738. doi:10.1161/HYPERTENSIONAHA.115.04889

Patiomer package insert. May 2020. Accessed May 27, 2020.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/205739s016lbl.pdf

Sodium zirconium cyclosilicate package insert. April 2020. Accessed May 27, 2020.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/207078s003lbl.pdf

Post 16

Núñez J, Bayés-Genis A, Zannad F, et al. Long-term potassium monitoring and dynamics in heart failure and risk of mortality. *Circulation.* 2018;137(13):1320-1330. doi:10.1161/CIRCULATIONAHA.117.030576

Post 17

Davis J, Israni R, Mu F, et al. Inpatient management and post-discharge outcomes of hyperkalemia [published online ahead of print, 2021 May 26]. *Hosp Pract (1995).* 2021;49(4):273-279. doi:10.1080/21548331.2021.1925554

Post 19

Hernandez AF, Greiner MA, Fonarow GC, et al. Relationship between early physician follow-up and 30-day readmission among Medicare beneficiaries hospitalized for heart failure. *JAMA*. 2010;303(17):1716-1722. doi:10.1001/jama.2010.533

Lema GF, Tesema HG, Fentie DY, Arefayne NR. Evidence-based perioperative management of patients with high serum potassium level in resource-limited areas: a systematic review. *Int J Surg Open*. 2019;21:21-29. doi:10.1016/j.ijso.2019.10.006

Rayan N, Baird R, Masica A. Rapid response team interventions for severe hyperkalemia: evaluation of a patient safety initiative. *Hosp Pract (1995)*. 2011;39(1):161-169.

Glossary

AEs, adverse effects
Approp, appropriate
BP, blood pressure
CKD, chronic kidney disease
Discont, discontinue
DM, diabetes mellitus
eGFR, estimated glomerular filtration rate
esp, especially
HD, hemodialysis
HF, heart failure
HK, hyperkalemia
HyperK, hyperkalemia
ID, initial diagnosis
NSAID, nonsteroidal anti-inflammatory drug
Pt, patient
RAASi, Renin-angiotensin-aldosterone system inhibitors
SP, sepharose
SPS, sodium polystyrene sulfonate
SZC, Sodium zirconium cyclosilicate
T2DM, Type 2 Diabetes Mellitus
Tx, treatment
w/, with
Wks, weeks
Yo, years old
yr, year